BACKGROUND AND OBJECTIVES: The aims of this study were to determine the frequency of venous thromboembolic events in a large cohort of patients with idiopathic membranous nephropathy and to identify predisposing risk factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied patients with biopsy-proven membranous nephropathy from the Glomerular Disease Collaborative Network (n=412) and the Toronto Glomerulonephritis Registry (n=486) inception cohorts. The cohorts were pooled after establishing similar baseline characteristics (total n=898). Clinically apparent and radiologically confirmed venous thromboembolic events were identified. Potential risk factors were evaluated using multivariable logistic regression models. RESULTS: Sixty-five (7.2%) subjects had at least one venous thromboembolic event, and this rate did not differ significantly between registries. Most venous thromboembolic events occurred within 2 years of first clinical assessment (median time to VTE = 3.8 months). After adjusting for age, sex, proteinuria, and immunosuppressive therapy, hypoalbuminemia at diagnosis was the only independent predictor of a venous thromboembolic event. Each 1.0 g/dl reduction in serum albumin was associated with a 2.13-fold increased risk of VTE. An albumin level <2.8 g/dl was the threshold below which risk for a venous thromboembolic event was greatest. CONCLUSIONS: We conclude that clinically apparent venous thromboembolic events occur in about 7% of patients with membranous nephropathy. Hypoalbuminemia, particularly <2.8 g/dl, is the most significant independent predictor of venous thrombotic risk.
BACKGROUND AND OBJECTIVES: The aims of this study were to determine the frequency of venous thromboembolic events in a large cohort of patients with idiopathic membranous nephropathy and to identify predisposing risk factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied patients with biopsy-proven membranous nephropathy from the Glomerular Disease Collaborative Network (n=412) and the Toronto Glomerulonephritis Registry (n=486) inception cohorts. The cohorts were pooled after establishing similar baseline characteristics (total n=898). Clinically apparent and radiologically confirmed venous thromboembolic events were identified. Potential risk factors were evaluated using multivariable logistic regression models. RESULTS: Sixty-five (7.2%) subjects had at least one venous thromboembolic event, and this rate did not differ significantly between registries. Most venous thromboembolic events occurred within 2 years of first clinical assessment (median time to VTE = 3.8 months). After adjusting for age, sex, proteinuria, and immunosuppressive therapy, hypoalbuminemia at diagnosis was the only independent predictor of a venous thromboembolic event. Each 1.0 g/dl reduction in serum albumin was associated with a 2.13-fold increased risk of VTE. An albumin level <2.8 g/dl was the threshold below which risk for a venous thromboembolic event was greatest. CONCLUSIONS: We conclude that clinically apparent venous thromboembolic events occur in about 7% of patients with membranous nephropathy. Hypoalbuminemia, particularly <2.8 g/dl, is the most significant independent predictor of venous thrombotic risk.
Authors: R D Farmer; R A Lawrenson; J C Todd; T J Williams; K D MacRae; F Tyrer; G M Leydon Journal: Br J Clin Pharmacol Date: 2000-06 Impact factor: 4.335
Authors: D C Cattran; C Greenwood; S Ritchie; K Bernstein; D N Churchill; W F Clark; P A Morrin; S Lavoie Journal: Kidney Int Date: 1995-04 Impact factor: 10.612
Authors: Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman Journal: Clin J Am Soc Nephrol Date: 2016-02-16 Impact factor: 8.237
Authors: Vasanth Sathiyakumar; Sarah E Greenberg; Alex A Jahangir; Hassan H Mir; William T Obremskey; Manish K Sethi Journal: Int Orthop Date: 2015-07-09 Impact factor: 3.075
Authors: Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels Journal: Clin J Am Soc Nephrol Date: 2014-05-22 Impact factor: 8.237
Authors: Taewoo Lee; Vimal K Derebail; Abhijit V Kshirsagar; Yunro Chung; Jason P Fine; Shannon Mahoney; Caroline J Poulton; Sophia Lionaki; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Michelle Hladunewich; Heather N Reich; Patrick H Nachman Journal: Kidney Int Date: 2016-02-26 Impact factor: 10.612